NEL RISPETTO DELLE NUOVE DISPOSIZIONI IN MATERIA DI ECM, A SEGUITO DELL ATTUAZIONE DELL ACCORDO STATO-REGIONI DEL 5/11/09 E SUCCESSIVE

Similar documents
The long-term impact of the low-fodmap diet for management of irritable bowel syndrome. Dr Miranda Lomer RD.

FUNCTIONAL DISORDERS TREATMENT ADVANCES. Dr. Adriana Lazarescu MD FRCPC Director GI Motility Lab, Edmonton Associate Professor University of Alberta

Primary Management of Irritable Bowel Syndrome

Presenter. Irritable Bowel Syndrome. Objectives. Introduction. Rome Criteria. Irritable Bowel Syndrome 2/28/2018

Advancing gastroenterology, improving patient care

William D. Chey, MD Professor of Medicine University of Michigan

IBS Irritable Bowel syndrome Therapeutics II PHCL 430

IBS: overview and assessment of pain outcomes and implications for inclusion criteria

Slide #43. Functional Disorders - An Update 11/8/ MA ACP Annual Scientific Meeting. Functional Disorders: An Update


Emerging Treatments for IBS-C and Clinical Trial Endpoints

Diagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider

Unlocking the mysteries of gut comfort

Evidence-based Treatment Strategies for

The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?

Unlocking the mysteries of gut comfort

Pharmacotherapy for IBS

Diagnosis and Treatment of Irritable Bowel Syndrome

Irritable Bowel Syndrome: Current and Emerging Treatment Options

David Leff, DO. April 13, Disclosure. I have the following financial relationships to disclosure:

Tenapanor for irritable bowel syndrome with constipation

Microbiome GI Disorders

Irritable Bowel Syndrome and Chronic Constipation. Treatment of IBS. Susan Lucak, M.D. Columbia University Medical Center

Evolving Therapy in Irritable Bowel Syndrome (IBS)

ALMIRALL AND IRONWOOD ANNOUNCE POSITIVE RESULTS FROM A PHASE 3 TRIAL WITH LINACLOTIDE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION

Chronic Abdominal Pain. Dr. Robert B. Smith Tupelo Digestive Health Specialists August 26, 2016

New Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome

ROME IV CRITERIA FOR IBS

OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA

Xifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary

Management of Functional Bowel Disorders

5 Things to Know About Irritable Bowel Syndrome

Outline. Definition (s) Epidemiology Pathophysiology Management With an emphasis on recent developments

Current and Emerging Pharmacological Treatments in Irritable Bowel Syndrome

Functional Dyspepsia

UKLIN1693a, date of preparation: March 2013.

Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation

... SELECTED ABSTRACTS...

Treatment of IBS - Diet or Drugs?

Efficacy and Safety of Lubiprostone. Laura Wozniak February 23, 2010 K30 Monthly Journal Club

Dr. Melvyn Letier Constantiaberg Mediclinic October 2016

Nicholas J. Talley, MD University of Newcastle Callaghan, NSW Australia. Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA

Why does my stomach hurt? Exploring irritable bowel syndrome

Irritable Bowel Syndrome. Mustafa Giaffer March 2017

The Leeds Teaching Hospitals NHS Trust Irritable Bowel Syndrome

The role of gut microbiome in IBS

Irritable bowel syndrome (IBS) is a ... PRESENTATION... Defining and Diagnosing Irritable Bowel Syndrome

Irritable Bowel Syndrome Now. George M. Logan, MD Friday, May 5, :35 4:05 PM

William D. Chey, MD, FACG. Page 1 of ACG Midwest Regional Postgraduate Course Copyright 2016 American College of Gastroenterology

UNDERSTANDING IBS AND CC Implications for diagnosis and management

Antidepressant Medication use is Associated with Abdominal Symptoms in People without a Functional Gastrointestinal Diagnosis

Irritable bowel syndrome in adults

IBS and Functional GI Disorders (FGIDs)

CHAPTER 11 Functional Gastrointestinal Disorders (FGID) Mr. Ashok Kumar Dept of Pharmacy Practice SRM College of Pharmacy SRM University

Irritable Bowel Syndrome and Chronic Constipation

Inflammatory or Irritable? (the bowel, not the speaker)

SIMPOSIO Il microbiota intestinale e la sua modulazione nelle patologie dell asse intestino cervello. Microbiota e IBS.

The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study

Irritable Bowel Disease. Dr. Alexandra Ilnyckyj MD

TREATMENT SOCIETY GUIDELINES FOR CONSTIPATION: WHAT IS NEW? FUNCTIONAL CONSTIPATION

fever a persistent unexplained change in bowel habit in somebody over 50 years of age a family history of bowel or ovarian cancer.

Is one of the most common chronic disorders. causing patients to seek medical treatment.

ROME FOUNDATION - FGIDs: YEAR IN REVIEW

MANAGEMENT OF CHRONIC CONSTIPATION BEYOND LAXATIVES

Accepted Article. Irritable bowel syndrome (IBS) subtypes: Nothing. Fermín Mearin Manrique. DOI: /reed /2016 Link: PDF

Slide #43. Disclosure of Financial Relationships. IBS: Is it in Your Head or Gut? Anthony Lembo, M.D. Associate Professor of Medicine

IBS - Definition. Chronic functional disorder of GI generally characterized by:

Disclosures. GI Motility Disorders. Gastrointestinal Motility Disorders & Irritable Bowel Syndrome

Understanding & Alleviating Constipation. Living (Well!) with Gastroparesis Program Warm-Up Class

Low FODMAP Dietary Approach For FGD/IBS. Our Experience. Charlotte McCamphill 19 th February 2015

What s the Latest? Rome III Criteria for IBS

State of the Art: Management of Irritable Bowel Syndrome

Disclosures. Objectives. Pre-Test Question 1. Pre-Test Question 2. Pre-Test Question 3 9/23/2016

Mirtazapine in diarrhea-predominant irritable bowel syndrome: an openlabel

William Chey, MD University of Michigan Ann Arbor, MI

IBS current status Peter Laszlo Lakatos

Functional Heartburn and Dyspepsia

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 April 2011

Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice

Current Pharmacological Treatment Options in Chronic Constipation and IBS with Constipation

Number of studies. Endoscopic finding. Number of subjects. Pooled prevalence 95% CI

IBS-D: What to Do When Typical Treatment Methods Fail

Post-Infectious Irritable Bowel Syndrome. John K. Marshall MD Division of Gastroenterology McMaster University

SESSION 5 2:30pm 3:45pm

10/10/16. Disclosures. Educational Objectives

Irritable Bowel Syndrome

Chronic constipation in the elderly

DOWNLOAD OR READ : IRRITABLE BOWEL SYNDROME ONE DISEASE SEVERAL OR NONE PERSPECTIVES IN DIGESTIVE DISEASES VOL 5 PDF EBOOK EPUB MOBI

Intestinal, non-intestinal, and extra-digestive response to linaclotide in patients with IBS-C: results at Week 4 predict sustained response

Irritable bowel syndrome: An overview of diagnosis and pharmacologic treatment

Treat primary. symptoms. Offer general lifestyle advice. Manage IBS according to the dominant symptom. Follow up. Symptoms do not improve

APDW 2016 Poster No. a90312

Psycho-pharmacologic Therapy. Objectives

Elderly Man With Chronic Constipation

Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: A meta-analysis of randomized controlled trials

Addendum to NICE guideline CG61, Irritable bowel syndrome in adults

A Meta-analysis of the Therapeutic Effects of Amitriptyline for Treating Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a chronic, potentially disabling

Rome III Criteria for IBS. Irritable Bowel Syndrome: What s the Latest? IBS: What s the Latest? Distinguishing IBS-C from CC

Calming the Colon: A Review of Irritable Bowel Syndrome

Transcription:

NOME E NUMERO DEL PROVIDER: I&C SRL - 5387 ECM N : 180726 TITOLO: XVII CONGRESSO NAZIONALE GISMAD SEDE: MILANO, HOTEL NHOW DATA: 09-10/03/2017 NEL RISPETTO DELLE NUOVE DISPOSIZIONI IN MATERIA DI ECM, A SEGUITO DELL ATTUAZIONE DELL ACCORDO STATO-REGIONI DEL 5/11/09 E SUCCESSIVE MODIFICHE, AL FINE DI GARANTIRE LA MASSIMA TRASPARENZA IN MATERIA DI CONFLITTO DI INTERESSI SI INFORMANO I DISCENTI CHE PRESSO IL DESK RELATORI SONO DISPONIBILI I DOCUMENTI ATTESTANTI LE EVENTUALI COLLABORAZIONI CHE I DOCENTI ABBIANO AVUTO NEL CORSO DELL ULTIMO BIENNIO CON AZIENDE FARMACEUTICHE E/O DIAGNOSTICHE DALLE QUALI SIA DERIVATA L EROGAZIONE DI COMPENSI O FINANZIAMENTI.

Stato dell arte sulla terapia dell IBS-C Maura Corsetti, MD PhD Nottingham Digestive Diseases Centre (NDDC) University of Nottingham UK

Why is important for gastroenterologists to study IBS? IBS account for up to 50% of consultations of gastroenterologists Corsetti M, Tack J et al. IBS Global Impact report

Rome IV Diagnostic Criteria for IBS Lacy BE, Gastroenterology 2016

Lacy BE, Gastroenterology 2016 Subtyping of IBS

The biopsychosocial model of IBS Predisposing factors Early trauma Abuse Family history of IBS Anxiety/Depression Triggering factors Infections Surgical operations Antibiotics Drugs Major loss Perpetuating factors Anxiety/Depression IBS Altered gut motility Visceral hypersensitivity Drossman DA, back in 1994

The psychological disturbances in IBS: cause or consequence?

The role of previous infections in IBS A systematic review has evaluated the results of studies reporting the percentage of infected individuals who develop PI-IBS and has found that between 4% and 36% of these subjects develop the functional disorder. PI-IBS has been described more frequently as consequence of bacterial infection than of a viral infection. PI-IBS can also occur in subjects with previous Clostridium Difficile infection and after a parasite infection. After 6 months from Clostridium infection, diagnosed by means of both culture and rapid immunoassay toxins detection, 25% of 205 patients without prior Rome III criteria IBS met this diagnosis. Rome Foundation Working Team on Post-Infectious IBS 2017

Gastroenterology 2004

Gut permeability: the key player in IBS Piche T, Neurogastroenterol Mot 2014

Interaction between biopsychosocial factors and neurodegeneration Drossman DA, Neurogastroenterol Mot 2015

The role of visceral hypersensitivity and altered motility in IBS

The colonic motility during Preprandial period Postprandial period Response to bisacodyl Healthy subjects n= 10 Painful constipation (treatment refractory) n= 15 + Symptoms Reduced number Painless constipation (treatment refractory) n= 10 No response n= 4 Corsetti M, FNM 2016

The effect of different foods on the small bowel water content as measured by MRI in health Hussein M, J Nutr 2015

The management of IBS

Which antispasmodic is effective in IBS-C? Ford AC, Am J Gastroenterol 2014; Camilleri M, Gut 2017

Laxatives

Am J Gastroenterol 2016

Antidepressants

The efficacy of antidepressants in IBS Ford AC, Am J Gastroenterol 2014

Which antidepressant is effective on pain in IBS-C? Ford AC, Am J Gastroenterol 2014

The use of antidepressants in IBS Dekel R, Expert Opin Investig Drugs 2013; Tornblom H, Neurogastroenterol Mot 2015

Linaclotide

Mechanism of action of linaclotide Corsetti M, United European Gastroenterol J 2013

Results of the phase III studies with linaclotide in IBS-C 26 week Corsetti M, United European Gastroenterol J 2013

Down-regulation of GC-C in patients with IBS-C DDW 2016

But how can we use these evidences?

1 Step: a good patient-doctor relationship! Explain IBS as hyper-reactive and hyper-sensitive gut and clarify it does not put the patient at risk of cancer Suggest simple and practical dietary and lifestyle advice of NICE guidelines

Then Linaclotide (290 µg 1 daily) Bloating: Low FODMAP diet Still abdominal pain: TCA Still abdominal pain but anxiety and depression: TCA and SSRI Still constipation: ballon expulsion test and if positive biofeedback if negative colonic transit time Rectal irrigation

Conclusions The state of the art treatment of IBS-C : - Remember the factors demonstrated to trigger the symptoms - Good patient-doctor relationship. - Some antispasmodics have been found to be effective in the short term but availability of the compounds across countries may limit their clinical application. - Peppermint oil has been found to be effective in the short-term. - Linaclotide has been recently approved by both FDA and EMA and demonstrated to be effective in the short- and in the long-term. - TCA and SSRI have been found to be effective but their clinical application is limited by adherence to treatment (doctors mistake!).

Lubiprostone

Mechanism of action of lubiprostone

Results of the phase III studies with lubiprostone in IBS-C Two phase-3 randomized trials of lubiprostone 8 mcg vs. placebo twice daily for 12 weeks in 1171 patients with a Rome II IBS-C Primary efficacy endpoint: % of overall responders (weekly assessments of symptom relief gathered from the responses to the question How would you rate your relief of IBS symptoms over the past week compared to how you felt before you entered the study? ) Drossman DA, Aliment Pharmacol Ther 2008

The effect of Lubiprostone on pain in IBS-C Drossman DA, Aliment Pharmacol Ther 2008

The role of previous surgical operations in IBS IBS receive twice as many appendectomies or hysterectomies, and two to three times as many cholecystectomies Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology. 2004;126:1665 73 Recent advances in insight into the underlying pathophysiology have identified intestinal inflammation triggered by handling of the intestine as the main mechanism for postoperative ileus. Boeckxstaens G, Gut 2009